search
Back to results

Goal-directed Analgesia Using ANI During General Anesthesia in Children With Moyamoya Disease

Primary Purpose

Pain

Status
Recruiting
Phase
Not Applicable
Locations
Korea, Republic of
Study Type
Interventional
Intervention
ANI (Analgesia/Nociception Index) monitoring
standard monitoring
Sufentanil
Sponsored by
Seoul National University Hospital
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional other trial for Pain

Eligibility Criteria

undefined - 18 Years (Child, Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Pediatric patients receiving EDAS surgery for Moyamoya disease Exclusion Criteria: ASA (American society of anesthsiologists classification) 4-5 Emergency surgery patients with chronic pain on medication

Sites / Locations

  • Seoul national university hospitalRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

ANI (Analgesia/Nociception Index) monitoring

Standard monitoring

Arm Description

Outcomes

Primary Outcome Measures

the mean hourly intraoperative sufentanil requirement

Secondary Outcome Measures

the amount of non-opioids analgesic requirements
the amount of vasoactive agents requirements

Full Information

First Posted
January 3, 2023
Last Updated
January 5, 2023
Sponsor
Seoul National University Hospital
search

1. Study Identification

Unique Protocol Identification Number
NCT05672212
Brief Title
Goal-directed Analgesia Using ANI During General Anesthesia in Children With Moyamoya Disease
Official Title
Effect of Goal-directed Analgesia Using ANI (Analgesia/Nociception Index) During General Anesthesia in Children Undergoing EDAS (Encephaloduroarteriosynangiosis) Surgery for Moyamoya Disease: a Randomized Controlled Trial
Study Type
Interventional

2. Study Status

Record Verification Date
January 2023
Overall Recruitment Status
Recruiting
Study Start Date
January 4, 2023 (Actual)
Primary Completion Date
January 4, 2025 (Anticipated)
Study Completion Date
January 4, 2025 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Seoul National University Hospital

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No

5. Study Description

Brief Summary
Analgesia Nociception Index (ANI) has been proposed for the evaluation of the nociception-antinociception balance in the perioperative period. In pediatric patients with Moyamoay disease, where the management of analgesia may be rendered difficult by pharmacological changes, we hypothesised that the monitoring of analgesia with ANI would reduce intraoperative opioid consumption during EDAS surgery.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Pain

7. Study Design

Primary Purpose
Other
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
40 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
ANI (Analgesia/Nociception Index) monitoring
Arm Type
Experimental
Arm Title
Standard monitoring
Arm Type
Active Comparator
Intervention Type
Device
Intervention Name(s)
ANI (Analgesia/Nociception Index) monitoring
Intervention Description
Intraoperative analgesia was provided by injection of sufentanil, which was performed according to ANI monitor.
Intervention Type
Device
Intervention Name(s)
standard monitoring
Intervention Description
Intraoperative analgesia was provided by injection of sufentanil, which was performed according to the clinician's assessment.
Intervention Type
Drug
Intervention Name(s)
Sufentanil
Intervention Description
Sufentanil
Primary Outcome Measure Information:
Title
the mean hourly intraoperative sufentanil requirement
Time Frame
from induction of anesthesia to end of operation, about 5 hours
Secondary Outcome Measure Information:
Title
the amount of non-opioids analgesic requirements
Time Frame
from induction of anesthesia to end of operation, about 5 hours
Title
the amount of vasoactive agents requirements
Time Frame
from induction of anesthesia to end of operation, about 5 hours

10. Eligibility

Sex
All
Maximum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Pediatric patients receiving EDAS surgery for Moyamoya disease Exclusion Criteria: ASA (American society of anesthsiologists classification) 4-5 Emergency surgery patients with chronic pain on medication
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Eun-hee Kim
Phone
+82-2-2072-3664
Email
beloveun@snu.ac.kr
Facility Information:
Facility Name
Seoul national university hospital
City
Seoul
Country
Korea, Republic of
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Eun-hee Kim

12. IPD Sharing Statement

Plan to Share IPD
Undecided

Learn more about this trial

Goal-directed Analgesia Using ANI During General Anesthesia in Children With Moyamoya Disease

We'll reach out to this number within 24 hrs